{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:53:58Z","timestamp":1780649638332,"version":"3.54.1"},"reference-count":33,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acromegaly treatment has greatly evolved in recent decades, but there are still patients whose acromegaly is not controlled with currently available treatments, and there is a need to improve the treatment burden. Fortunately, there are new treatments under development that may increase treatment efficacy and convenience.<\/jats:p>","DOI":"10.1210\/clinem\/dgad568","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T22:33:37Z","timestamp":1695854017000},"page":"e1323-e1327","source":"Crossref","is-referenced-by-count":9,"title":["New Treatments for Acromegaly in Development"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9250-3558","authenticated-orcid":false,"given":"M\u00f4nica R","family":"Gadelha","sequence":"first","affiliation":[{"name":"Endocrine Unit and Neuroendocrinology Research Center, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho\u2014Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 , Brazil"},{"name":"Neuroendocrine Unit\u2014Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Secretaria Estadual de Sa\u00fade , Rio de Janeiro 20231-092 , Brazil"},{"name":"Neuropathology and Molecular Genetics Laboratory, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Secretaria Estadual de Sa\u00fade , Rio de Janeiro 20231-092 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina","family":"Gadelha","sequence":"additional","affiliation":[{"name":"Endocrine Unit and Neuroendocrinology Research Center, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho\u2014Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Kasuki","sequence":"additional","affiliation":[{"name":"Endocrine Unit and Neuroendocrinology Research Center, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho\u2014Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 , Brazil"},{"name":"Neuroendocrine Unit\u2014Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Secretaria Estadual de Sa\u00fade , Rio de Janeiro 20231-092 , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"1","key":"2024031503425530500_dgad568-B1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"issue":"4","key":"2024031503425530500_dgad568-B2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"2024031503425530500_dgad568-B3","doi-asserted-by":"crossref","first-page":"101264","DOI":"10.1016\/j.beem.2019.02.001","article-title":"National acromegaly registries","volume":"33","author":"Maione","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2024031503425530500_dgad568-B4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"2024031503425530500_dgad568-B5","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1210\/clinem\/dgac643","article-title":"Acrobat edge: safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly","volume":"108","author":"Gadelha","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024031503425530500_dgad568-B6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: long-term outcomes from an extension to the phase III (PAOLA) study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"2024031503425530500_dgad568-B7","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fendo.2019.00931","article-title":"Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs","volume":"10","author":"Gadelha","year":"2019","journal-title":"Front Endocrinol"},{"issue":"3","key":"2024031503425530500_dgad568-B8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2024031503425530500_dgad568-B9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2024031503425530500_dgad568-B10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024031503425530500_dgad568-B11","doi-asserted-by":"crossref","first-page":"101679","DOI":"10.1016\/j.beem.2022.101679","article-title":"Innovative therapeutics in acromegaly","volume":"36","author":"Kasuki","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"2024031503425530500_dgad568-B12","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1080\/14656566.2021.1908998","article-title":"New and emerging pharmacological treatment options for acromegaly","volume":"22","author":"Antunes","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"2024031503425530500_dgad568-B13","doi-asserted-by":"crossref","first-page":"R274","DOI":"10.1530\/EC-20-0433","article-title":"Novel therapies for acromegaly","volume":"9","author":"Maia","year":"2020","journal-title":"Endocr Connect"},{"issue":"1","key":"2024031503425530500_dgad568-B14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1021\/acsmedchemlett.2c00431","article-title":"Discovery of paltusotine (CRN00808), a potent, selective, and orally bioavailable non-peptide SST2 agonist","volume":"14","author":"Zhao","year":"2023","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"2024031503425530500_dgad568-B15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/eje.1.02313","article-title":"Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and nonfunctioning pituitary adenomas","volume":"156","author":"Taboada","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2024031503425530500_dgad568-B16","first-page":"AEP627","article-title":"Absolute oral bioavailability and absorption, metabolism, excretion of [14C]-labeled paltusotine (CRN00808), an orally bioavailable, nonpeptide, selective, somatostatin receptor 2 (sst2) biased agonist for the treatment of acromegaly","volume":"70","author":"Madan","year":"2020","journal-title":"Endocrine Abstracts"},{"issue":"2","key":"2024031503425530500_dgad568-B17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11102-021-01201-z","article-title":"Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers","volume":"25","author":"Madan","year":"2022","journal-title":"Pituitary"},{"issue":"2","key":"2024031503425530500_dgad568-B18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1009980404404","article-title":"Results of a European multicentre study with sandostatin LAR in acromegalic patients. Sandostatin LAR group","volume":"1","author":"Lancranjan","year":"1999","journal-title":"Pituitary"},{"issue":"1","key":"2024031503425530500_dgad568-B19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s41687-023-00541-7","article-title":"Development and evaluation of the acromegaly symptom diary","volume":"7","author":"Martin","year":"2023","journal-title":"J Patient Rep Outcomes"},{"key":"2024031503425530500_dgad568-B20","first-page":"P80","article-title":"Acrobat advance: progress report on a study of long-term safety and efficacy of paltusotine for the treatment of acromegaly","volume":"77","author":"Randeva","year":"2021","journal-title":"Endocrino Abstracts"},{"key":"2024031503425530500_dgad568-B21","article-title":"Oral, oncedaily, paltusotine (non-peptide selective somatostatin receptor subtype 2 agonist) therapy in patients with acromegaly is associated with long-term biochemical and symptom control and is preferred over injectable somatostatin-receptor ligands","author":"Gadelha","year":"2023"},{"issue":"Supplement_1","key":"2024031503425530500_dgad568-B22","doi-asserted-by":"crossref","first-page":"A524","DOI":"10.1210\/jendso\/bvab048.1068","article-title":"Pharmacokinetics and safety of an improved oral formulation of paltusotine, a selective, non-peptide somatostatin receptor 2 (SST2) agonist for the treatment of acromegaly","volume":"5","author":"Luo","year":"2021","journal-title":"J Endocr Soc"},{"issue":"10","key":"2024031503425530500_dgad568-B23","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1246\/cl.2012.1090","article-title":"Phase behavior, functions, and medical applications of soy phosphatidylcholine and diglyceride lipid compositions","volume":"41","author":"Tiberg","year":"2012","journal-title":"Chem Lett"},{"issue":"1","key":"2024031503425530500_dgad568-B24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1773-2247(11)50009-7","article-title":"Drug delivery applications of non-lamellar liquid crystalline phases and nanoparticles","volume":"21","author":"Tiberg","year":"2011","journal-title":"J Drug Delivery Science Techn"},{"issue":"3","key":"2024031503425530500_dgad568-B25","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bcp.12698","article-title":"Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers","volume":"80","author":"Tiberg","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2024031503425530500_dgad568-B26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00280-018-3734-1","article-title":"Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study","volume":"83","author":"Pavel","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024031503425530500_dgad568-B27","author":"Ferone","year":"2023"},{"issue":"Suppl 2","key":"2024031503425530500_dgad568-B28","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1530\/eje.0.148s021","article-title":"Discovery and mechanism of action of pegvisomant","volume":"148","author":"Kopchick","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"2024031503425530500_dgad568-B29","doi-asserted-by":"crossref","first-page":"100588","DOI":"10.1016\/j.jbc.2021.100588","article-title":"A novel peptide antagonist of the human growth hormone receptor","volume":"296","author":"Basu","year":"2021","journal-title":"J Biol Chem"},{"key":"2024031503425530500_dgad568-B30","doi-asserted-by":"crossref","first-page":"105030","DOI":"10.1016\/j.jbc.2023.105030","article-title":"Structure and function of a dual antagonist of the human growth hormone and prolactin receptors with sitespecific PEG conjugates","volume":"299","author":"Basu","year":"2023","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"2024031503425530500_dgad568-B31","doi-asserted-by":"crossref","first-page":"A511","DOI":"10.1210\/jendso\/bvac150.1062","article-title":"Sustained suppression of IGF1 with AZP-3813, a bicyclic 16-amino acid peptide antagonist of the human growth hormone receptor and a potential new treatment for acromegaly","volume":"6","author":"Culler","year":"2022","journal-title":"J Endocr Soc"},{"key":"2024031503425530500_dgad568-B32","first-page":"P148","article-title":"AZP-3813, a bicyclic 16-amino acid peptide antagonist of the human growth hormone receptor as a potential new treatment for acromegaly","volume":"81","author":"Milano","year":"2022","journal-title":"Endocr Abstr"},{"key":"2024031503425530500_dgad568-B33","author":"Ravel","year":"2023"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad568\/52031321\/dgad568.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/4\/e1323\/56950062\/dgad568.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/109\/4\/e1323\/56950062\/dgad568.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T03:43:18Z","timestamp":1710474198000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/4\/e1323\/7283885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,9,27]]},"published-print":{"date-parts":[[2024,3,15]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad568","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2023,9,27]]}}}